News Quantified

PFSA – profusa, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025

Profusa (NASDAQ:PFSA) is now covered by analysts at Weiss Ratings. They set a "sell (e+)" rating on the stock.

Profusa Announces Third Quarter Business and Financial Highlights [Yahoo! Finance]

Profusa Announces Third Quarter Business and Financial Highlights

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}